Zevra Therapeutics (ZVRA) EPS (Basic) (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly EPS (Basic) came in at $0.65 in Q1 2026, up 1232.43% YoY from $0.05 in Q1 2025, and up 194.96% on a QoQ basis from $0.22 in Q4 2025.
Powered by 
Analysis
Zevra Therapeutics (ZVRA) EPS (Basic) (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of EPS (Basic) data on file, last reported at $0.65 in Q1 2026.
- Quarterly EPS (Basic) rose 1232.43% year-over-year to $0.65 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.13 (up 225.07% YoY) and the FY2025 annual result came in at $1.5, up 165.96% from the prior year.
- EPS (Basic) grew to $0.65 in Q1 2026, from $0.22 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of $1.36 in Q2 2025 to a low of -$0.77 in Q4 2024.
- A 5-year average of -$0.16 and a median of -$0.26 in 2022 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2023 — EPS (Basic) sank 532.01% — and 2026, when it surged 1232.43%.
- Tracing ZVRA's EPS (Basic) over 5 years: stood at -$0.26 in 2022, then sank by 114.52% to -$0.56 in 2023, then plunged by 37.72% to -$0.77 in 2024, then soared by 128.46% to $0.22 in 2025, then surged by 194.96% to $0.65 in 2026.
- The last three EPS (Basic) figures came in at $0.65 (Q1 2026), $0.22 (Q4 2025), and -$0.01 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -3.06 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.18 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.06 |
| 10 | Zevra Therapeutics | 734.60 Mn | 513.03 Mn | 38.18 Mn | 0.15 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.15 |
| Mar 31, 2026 | 0.65 |
| Dec 31, 2025 | 0.22 |
| Sep 30, 2025 | -0.01 |
| Jun 30, 2025 | 1.36 |
| Mar 31, 2025 | -0.06 |
| Dec 31, 2024 | -0.77 |
| Sep 30, 2024 | -0.69 |
| Jun 30, 2024 | -0.48 |
| Mar 31, 2024 | -0.40 |
| Dec 31, 2023 | -0.56 |
| Sep 30, 2023 | -0.30 |
| Jun 30, 2023 | -0.08 |
| Mar 31, 2023 | -0.34 |
| Dec 31, 2022 | -0.26 |
| Sep 30, 2022 | -0.10 |
| Jun 30, 2022 | -0.35 |
| Mar 31, 2022 | -0.03 |
| Dec 31, 2021 | -0.05 |
| Sep 30, 2021 | -0.02 |